Drug Profile
HE 2100
Alternative Names: HE2100; NEUMUNELatest Information Update: 24 May 2011
Price :
$50
*
At a glance
- Originator Virginia Commonwealth University
- Developer Armed Forces Radiobiology Research Institute
- Class Androstenediols; Radioprotectives; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Neutropenia; Nosocomial infections; Radiation injuries
Most Recent Events
- 20 Mar 2007 HE 2100 is available for licensing (http://www.holliseden.com)
- 17 Mar 2007 Discontinued - Phase-I for Radiation injuries in Netherlands (Injection)
- 17 Mar 2007 Discontinued - Phase-I for Radiation injuries in USA (Injection)